U.S. markets closed
  • S&P 500

    4,337.44
    +17.38 (+0.40%)
     
  • Dow 30

    34,006.88
    +43.04 (+0.13%)
     
  • Nasdaq

    13,271.32
    +59.51 (+0.45%)
     
  • Russell 2000

    1,784.24
    +7.74 (+0.44%)
     
  • Crude Oil

    89.92
    -0.11 (-0.12%)
     
  • Gold

    1,935.00
    -10.60 (-0.54%)
     
  • Silver

    23.39
    -0.46 (-1.93%)
     
  • EUR/USD

    1.0595
    -0.0052 (-0.49%)
     
  • 10-Yr Bond

    4.5420
    +0.1040 (+2.34%)
     
  • GBP/USD

    1.2214
    -0.0026 (-0.21%)
     
  • USD/JPY

    148.8340
    +0.4740 (+0.32%)
     
  • Bitcoin USD

    26,370.23
    -63.10 (-0.24%)
     
  • CMC Crypto 200

    563.92
    +4.41 (+0.79%)
     
  • FTSE 100

    7,623.99
    -59.92 (-0.78%)
     
  • Nikkei 225

    32,678.62
    +276.21 (+0.85%)
     

Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc.

IRVINE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, Chief Executive Officer, will present at the upcoming SVB Securities Global Biopharma Conference on February 15, 2023, at 5:00 p.m. ET.

To register in advance for the presentation webcast, sign up here.

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper 
Gilmartin Group 
(858) 525-2047 
stephen@gilmartinir.com

Source: Eledon Pharmaceuticals